Similar Papers

Paper Title
Journal
Date
Author
Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study
Xiao Shang ... Fengzhi Feng
International Journal of Gynecologic Cancer | VOL. 34
Xiao Shang, et. al.Xiao Shang ... Fengzhi Feng
24 Apr 2024
Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
Floor Backes ... David O'Malley
Gynecologic Oncology | VOL. 162
Floor Backes, et. al.Floor Backes ... David O'Malley
01 Aug 2021
Combination therapy with pegylated liposomal doxorubicin and carboplatin in malignant gynecologic tumors. A prospective multicenter phase II trial of the AGO-OVAR and the AGO Kommission Uterus (AGO-K-Ut)
F Hilpert ... P Wimberger
Journal of Clinical Oncology | VOL. 24
F Hilpert, et. al.F Hilpert ... P Wimberger
20 Jun 2006
Comparison of tumor microbiota between primary and recurrent or metastatic sites in women with advanced or relapsed endometrial and ovarian cancer (240)
Jillian O’Donnell ... Amber Mccoy
Gynecologic Oncology | VOL. 166
Jillian O’Donnell, et. al.Jillian O’Donnell ... Amber Mccoy
01 Aug 2022
View more papers

More From: Gynecologic Oncology

Paper Title
Journal
Date
Author
Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management.
Andrea Neilson ... Jessica N Mcalpine
Gynecologic oncology | VOL. 193
Andrea Neilson, et. al.Andrea Neilson ... Jessica N Mcalpine
01 Feb 2025
What happens after menopause? (WHAM): A prospective controlled study of cognition 24months after premenopausal risk-reducing salpingo-oophorectomy.
Pauline M Maki ... Martha Hickey
Gynecologic oncology | VOL. 193
Pauline M Maki, et. al.Pauline M Maki ... Martha Hickey
01 Feb 2025
Added prognostic value of sentinel lymph node mapping in endometrial cancer to molecular subgroups
Franziska Siegenthaler ... Michael D Mueller
Gynecologic Oncology | VOL. 193
Franziska Siegenthaler, et. al.Franziska Siegenthaler ... Michael D Mueller
01 Feb 2025
Barriers to early detection: Insurance denials for breast MRI screening in women with germline BRCA1/2 mutations
S Gordhandas ... E Aviki
Gynecologic Oncology | VOL. 193
S Gordhandas, et. al.S Gordhandas ... E Aviki
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.